Statement of Changes in Beneficial Ownership (4)
August 13 2021 - 5:36PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
CRANDELL KEITH |
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp
[
TWST
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
C/O ARCH VENTURE PARTNERS IX, LLC, 8755 W. HIGGINS ROAD, SUITE 1025 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/12/2021 |
|
(Street)
CHICAGO, IL 60631
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 8/12/2021 | | S | | 1412 | D | $106.93 | 486 | D | |
| Common Stock | 8/12/2021 | | S | | 41033 | D | $106.9765 (6) | 78602 | I | By Keith L. Crandell Trust |
| Common Stock | 8/12/2021 | | S | | 2555 | D | $107.5638 (7) | 76047 | I | By Keith L. Crandell Trust |
| Common Stock | 2/11/2021 | | J(1)(5) | | 286480 | D | $0 | 440354 | I | By Arch Venture Fund VII, L.P. (2)(4) |
| Common Stock | 2/11/2021 | | J(1)(5) | | 14560 | A | $0 | 97252 | I | By Keith L. Crandell Trust |
| Common Stock | 2/11/2021 | | J(1)(5) | | 113520 | D | $0 | 174584 | I | By ARCH Venture Fund VIII Overage, L.P. (3)(4) |
| Common Stock | 2/11/2021 | | J(1)(5) | | 1 | A | $0 | 97253 | I | By Keith L. Crandell Trust |
| Common Stock | 5/13/2021 | | J(1)(5) | | 214828 | D | $0 | 225526 | I | By ARCH Venture Fund VII, L.P. (2)(4) |
| Common Stock | 5/13/2021 | | J(1)(5) | | 10918 | A | $0 | 108171 | I | By Keith L. Crandell Trust |
| Common Stock | 5/13/2021 | | J(1)(5) | | 85172 | D | $0 | 89412 | I | By ARCH Venture Fund VIII Overage, L.P. (3)(4) |
| Common Stock | 5/13/2021 | | J(1)(5) | | 1 | A | $0 | 108172 | I | By Keith L. Crandell Trust |
| Common Stock | 5/19/2021 | | J(1)(5) | | 225526 | D | $0 | 0 | I | By ARCH Venture Fund VII, L.P. (2)(4) |
| Common Stock | 5/19/2021 | | J(1)(5) | | 11462 | A | $0 | 119634 | I | By Keith L. Crandell Trust |
| Common Stock | 5/19/2021 | | J(1)(5) | | 89412 | D | $0 | 0 | I | By ARCH Venture Fund VIII Overage, L.P. (3)(4) |
| Common Stock | 5/19/2021 | | J(1)(5) | | 1 | A | $0 | 119635 | I | By Keith L. Crandell Trust |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | Pro-rata distribution of Common Stock held by a limited partnership to its partners for no consideration. |
| (2) | The shares were directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| (3) | The shares were directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| (4) | Keith Crandell is a managing director of ARCH VII LLC and ARCH VIII LLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| (5) | Change in form of ownership of shares previously reported as beneficially owned by the reporting person. |
| (6) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.39 to $107.37. The reporting person undertakes to provide to TWST, any security holder of TWST, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4. |
| (7) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.405 to $107.70. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
CRANDELL KEITH
C/O ARCH VENTURE PARTNERS IX, LLC
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL 60631 | X |
|
|
|
Signatures
|
| /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell | | 8/13/2021 |
| **Signature of Reporting Person | Date |
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024
